Dedifferentiation-reprogrammed human
mesenchymal stem cells for treating ischaemic
stroke: abridged secondary publication
X Zhang1,2,3, F Yang1,2, R Chen1,2, L Tsang1,2, X Jiang1,2,4, H Chan1,2,3,4
1 Epithelial Cell Biology Research Centre, The Chinese University of Hong Kong
2 School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong
3 Sichuan University-The Chinese University of Hong Kong Joint Laboratory for Reproductive Medicine, West China Second University Hospital, Chengdu
4 The Chinese University of Hong Kong, Shenzhen Research Institute, Shenzhen
1. Dedifferentiated-reprogrammed human
mesenchymal stem cells (De-neu-hMSCs)
reveal distinguished stem cell phenotype such as
enhanced neuronal differentiation potential, cell
migration, and cell survival, compared with naïve
hMSCs.
2. Systemic administration of hMSCs/De-neuhMSCs significantly improves stroke recovery, with De-neu-hMSCs exhibiting stronger repair function.
3 De-neu-hMSC treatment results in more improved motor function recovery and less brain damage, compared with hMSC treatment.
4 The enhanced therapeutic effects of De-neu-hMSCs might be attributed to suppression of endogenous Bax-induced apoptosis pathway.
2. Systemic administration of hMSCs/De-neuhMSCs significantly improves stroke recovery, with De-neu-hMSCs exhibiting stronger repair function.
3 De-neu-hMSC treatment results in more improved motor function recovery and less brain damage, compared with hMSC treatment.
4 The enhanced therapeutic effects of De-neu-hMSCs might be attributed to suppression of endogenous Bax-induced apoptosis pathway.